Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022GlobeNewsWire • 10/07/22
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular DystrophyGlobeNewsWire • 09/29/22
Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027GlobeNewsWire • 09/14/22
Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027GlobeNewsWire • 09/12/22
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic YearGlobeNewsWire • 09/07/22
Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/22
Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 09/06/22
Why Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report?Zacks Investment Research • 09/01/22
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, AxsomeInvestors Business Daily • 08/30/22
Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic DiseasesGlobeNewsWire • 08/08/22
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/02/22
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/02/22
Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 08/02/22
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength?Zacks Investment Research • 08/01/22